Good morning from the Financial Times. Today is Tuesday, June 22nd, and this is your FT news briefing.

The top US drug regulator is facing calls to step down. The beleaguered,

shipping industry struggles with another disruption, and Tokyo finally makes a decision on whether

the Olympics will have fans in the stands. Plus, the US Supreme Court came to a unanimous decision

on college athletics yesterday. It speaks to a wider public opinion which over time has shifted

in favor of student athletes' rights rather than the institution of the NCAA.

I'm Mark Filipino, and here's the news you need to start your day.

The Commissioner of the US Food and Drug Administration is facing calls for her removal.

This follows the FDA's controversial approval last month of a new Alzheimer's treatment.

Janet Woodcock was appointed acting commissioner while the search for a permanent replacement

continued, critics say she's too cozy with the drug industry. Three members of the FDA's advisory

panel quit after the Alzheimer's treatment was approved. The panel had unanimously opposed it

last year. Many doubt the efficacy of the treatment, which is made by biogen and will cost

patients $56,000 a year, one member of the panel said it probably was the worst drug-approval

decision in recent US history. Woodcock did not respond to the FDA's request for comment.

Just when the shipping industry was getting back on its feet from all the disruption

brought by the pandemic and the Suez Canal blockage, it's reeling from another blow. A huge

terminal in one of the biggest ports in the world was shut down because of a COVID outbreak.

Chinese authorities closed the NTN terminal for almost a week last month,

but operations still aren't back to normal. The FDA's Harry Dempsey describes the impact.

This is an absolutely massive terminal, and the amount of cargo that was affected

was even larger than the amount of cargo that was held up when the Suez Canal was blocked.

...